about
Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data.Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.Relevance of timing for determination of posaconazole plasma concentrationsPathogen-specific DNA enrichment does not increase sensitivity of PCR for diagnosis of invasive aspergillosis in neutropenic patientsPharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative.A novel extraction method combining plasma with a whole-blood fraction shows excellent sensitivity and reproducibility for patients at high risk for invasive aspergillosis.Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients.CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Caspofungin for treatment of invasive aspergillus infections.Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive Aspergillosis enhances diagnostic capabilitiesPrimary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA-microarray from primary clinical samples.Medical diagnostics for indoor mold exposure.Rapid PCR test for discriminating between Candida albicans and Candida dubliniensis isolates using primers derived from the pH-regulated PHR1 and PHR2 genes of C. albicans.Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals.Endophthalmitis as primary clinical manifestation of fatal fusariosis in an allogeneic stem cell recipient.Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: resuIsavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.Prospective multicentre PCR-based Aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis.Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.[Patient with COPD after allogeneic hematopoietic stem cell transplantation with cough and subfebrile temperature].Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.Forty-one recent cases of invasive zygomycosis from a global clinical registry.Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation.Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice.Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.
P50
Q30884873-CBAD12C6-5380-4EAD-9F6C-7024FD393B2FQ33798313-EA8530FE-3C62-41E8-9F35-9B55A84F75D8Q34151170-94F12CCD-90C2-45E6-9E04-3F7F53514469Q34451601-CFED9CE8-582E-4F56-BB06-EE8E8ACEEBC3Q35065721-C7822A1F-6B03-45DF-90DE-33F59C321599Q35067116-FAAFFBBB-91A5-435C-8C18-83347C0FA25CQ35941414-1E88E65D-A500-4DC8-9146-EC26F95572AEQ35968600-20117BDE-8903-42CD-8508-2A843EA2038BQ36171444-2C5F8710-14E0-44AC-B639-1FD6ABEAB06CQ36826645-9983EFBE-0ABC-4568-B79A-E3DDA8E949CCQ37041199-583C0BF7-EC49-4041-9A48-D186ADC5F9E3Q37159584-F5544784-A0CD-47BA-93B5-A306A7BAE22BQ37293269-CFAAC75A-645A-4F14-B772-9A1D2AC3F836Q37336198-0EE78F7B-3746-4D45-9266-FC93D362AD93Q37344532-6E81931E-B0E9-4F08-BAA8-70D6C863F9AAQ37469829-8BD58000-446D-4E7E-9E8C-428CA2BE9039Q38013661-9F139A6E-FAE6-4793-B91C-21DCC8F03FBAQ38770830-870E87CF-5F62-4697-BE35-FCE8AAA6D2EEQ38811538-557E522A-EC3D-40D2-A047-FF1D4F7C9FEFQ38871233-F2964DA1-1FCA-44DD-A5F4-604B87CA9027Q38912624-022C21C6-073E-4C15-8DF8-8BFA65C4054DQ39041804-5F751157-3AC5-4A1C-8EB9-0A6C2F438E24Q39448963-B46AFE6D-ACA9-4622-9DF7-8010FEA1B39DQ40236833-B3727169-EFF8-46A3-BFBA-12786CE10B6AQ40334148-1A1FF5BF-08B9-46B6-9AEB-AD3BEAF9A1E0Q40413232-3CEB59D9-B23B-4B06-BC95-1E4CA2A4B86DQ40517272-02EB142F-DD9C-4BDB-B8A0-20E76E264319Q40620405-A63B5A55-A838-4808-B17E-49215517A122Q40865179-10C712FA-11BC-4692-B6A1-27B76E3C9F9FQ40984923-280BAA35-12D4-4861-92A9-665BFFB3AF96Q41676735-F691BB02-55D6-4F09-B992-C32C8EF9607EQ41692994-9482FCA6-F83D-4368-8084-CA270A0A17F6Q41868987-C2206299-A9C3-471F-8001-1BDCF85A1613Q42285675-833160B4-F705-4A58-819F-F289CF08AEB8Q42958723-75F04C1A-B5E4-4523-B97E-6FAE75C31E75Q43198289-99AA4FDF-6279-4D3F-817D-2DC96C42B455Q43223060-D74D4D51-63AA-4C4C-AADC-C210D1153A1FQ43232025-5B1A5508-5AC2-4A6B-87B5-310ACB6B8F83Q43500165-C337215D-6288-4B36-AF14-A6C01EAE573AQ44162406-A27D9638-B5C7-46E3-82C8-2E5C7CAF69FB
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Werner J Heinz
@ast
Werner J Heinz
@en
Werner J Heinz
@es
Werner J Heinz
@nl
Werner J Heinz
@sl
type
label
Werner J Heinz
@ast
Werner J Heinz
@en
Werner J Heinz
@es
Werner J Heinz
@nl
Werner J Heinz
@sl
altLabel
Heinz W
@en
prefLabel
Werner J Heinz
@ast
Werner J Heinz
@en
Werner J Heinz
@es
Werner J Heinz
@nl
Werner J Heinz
@sl
P214
P106
P21
P214
P31
P496
0000-0002-7833-9202
P734
P735
P7859
viaf-18138621